Cell Therapy:Market Insight, CDMO Pricing and Competitor Benchmarking
Back to Report Page

Cell Therapy:
Market Insight, CDMO Pricing and Competitor Benchmarking

Cell Therapy Pricing Update
Recent updates to our manufacturing process and strategic pricing study, designed to provide CDMOs with a competitive edge.
Digital Pricing Study
Digital Pricing Study
45+ Vetted CDMO Profiles
45+ Vetted CDMO Profiles
Cell Therapy Clinical Trial Analysis
Cell Therapy Clinical Trial Analysis
Global Biopharma Market
Global Biopharma Market
Cell Therapy Manufacturing Challenges and Innovations
Cell Therapy Manufacturing Challenges and Innovations
CDMO Service Comparison
CDMO Service Comparison

Over 500 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Cell Therapy: Market Insight, CDMO Pricing and Competitor Benchmarking study.

About This Report

  • This year we split the 2023 Cell and Gene Therapy report by modality, so that we can dive deeper into the production of cell therapies.

  • We have provided pricing for a typical mesenchymal stem cell therapy project in 2024. We now offer a unique perspective as we can comment on drivers of cell therapy manufacturing pricing.

  • We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.     

  • We obtained input from subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services. 

  • We put the manufacturing market in context of ongoing geopolitical news.

Study Methodology

  • For the first edition of Nice Insight’s Cell Therapy: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking study we have focused only on the cell therapies from our previous report. We updated all of our trends sections with up-to-date primary, proprietary data and a survey of secondary data from the published literature and industry databases to create a comprehensive outsourced development and manufacturing of cell therapies. The quantitative research that we performed is supplemented by direct interviews conducted with multiple SMEs with diverse roles in the sector to obtain qualitative perspectives on the dynamics of the space.

  • The content included here reflects in total over 1,000 hours of dedicated research, interviews, analysis, and composition, both to develop the 2024 pricing study and survey of clinical trials published.

  • A team comprising six Ph.D.-level experts collaborated with a group of 25+ existing clients representing CDMOs within the cell therapy manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.

  • Our staff with over 100 years of industry experience worked for over two months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.

  • Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.

Next Section
Section I: View from the Top: Success and Promise of Cell Therapies